Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Share-based Compensation (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Share-based Compensation for 4 consecutive years, with $1.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation fell 80.92% year-over-year to $1.2 million, compared with a TTM value of $14.1 million through Sep 2025, down 54.7%, and an annual FY2024 reading of $27.0 million, down 40.51% over the prior year.
  • Share-based Compensation was $1.2 million for Q3 2025 at Atara Biotherapeutics, down from $2.8 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $14.3 million in Q1 2022 and bottomed at $1.2 million in Q3 2025.
  • Average Share-based Compensation over 4 years is $9.0 million, with a median of $9.9 million recorded in 2023.
  • The sharpest move saw Share-based Compensation decreased 11.09% in 2023, then tumbled 80.92% in 2025.
  • Year by year, Share-based Compensation stood at $11.4 million in 2022, then fell by 12.64% to $9.9 million in 2023, then tumbled by 41.11% to $5.8 million in 2024, then crashed by 79.05% to $1.2 million in 2025.
  • Business Quant data shows Share-based Compensation for ATRA at $1.2 million in Q3 2025, $2.8 million in Q2 2025, and $4.2 million in Q1 2025.